MEI Pharma (MEIP) Stock Forecast, Price & News

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for MEI Pharma in the last year. There are currently 1 sell rating, 4 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" MEIP shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MEIP, but not buy additional shares or sell existing shares.
View MEIP analyst ratings or view top-rated stocks.

6 equities research analysts have issued 12-month price objectives for MEI Pharma's shares. Their MEIP share price forecasts range from $9.00 to $40.00. On average, they predict the company's share price to reach $29.67 in the next year. This suggests a possible upside of 325.0% from the stock's current price.
View analysts price targets for MEIP or view top-rated stocks among Wall Street analysts.

MEI Pharma's stock was trading at $4.8720 at the beginning of 2023. Since then, MEIP stock has increased by 43.3% and is now trading at $6.98.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.
View our MEIP earnings forecast.

MEI Pharma, Inc. (NASDAQ:MEIP) released its earnings results on Wednesday, November, 10th. The company reported ($2.60) EPS for the quarter, meeting the consensus estimate of ($2.60). The business had revenue of $13.39 million for the quarter, compared to the consensus estimate of $9.98 million. MEI Pharma had a negative trailing twelve-month return on equity of 92.47% and a negative net margin of 65.22%.

Shares of MEI Pharma reverse split on Monday, April 17th 2023. The 1-20 reverse split was announced on Monday, April 17th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, April 17th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other MEI Pharma investors own include Inovio Pharmaceuticals (INO), Rigel Pharmaceuticals (RIGL), Gilead Sciences (GILD), Novavax (NVAX), Dynavax Technologies (DVAX), SCYNEXIS (SCYX), OPKO Health (OPK), VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE) and TherapeuticsMD (TXMD).

MEI Pharma trades on the NASDAQ under the ticker symbol "MEIP."

Shares of MEIP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MEIP stock can currently be purchased for approximately $6.98.

MEI Pharma (NASDAQ:MEIP) has a market capitalization of $46.49 million and generates $48.82 million in revenue each year. The company earns $-31,840,000.00 in net income (profit) each year or ($4.63) on an earnings per share basis.

MEI Pharma's mailing address is 11455 EL CAMINO REAL SUITE 250, SAN DIEGO CA, 92130. The official website for the company is www.meipharma.com. The company can be reached via phone at (858) 369-7100, via email at investor@meipharma.com, or via fax at 302-655-5049.